Effects of Valsartan in Combination with Febuxostat on Serum Uric Acid, high-sensitivity C-reactive protein and Cardiac Function of Patients with Chronic Kidney Disease Plus Hyperuricemia

We aimed to evaluate the effects of valsartan in combination with febuxostat on serum uric acid, highsensitivity C-reactive protein and cardiac function of patients with chronic kidney disease plus hyperuricemia (HUA). A total of 144 patients with chronic kidney disease and hyperuricemia treated from June 2014 to June 2018 were retrospectively analyzed. They were divided into group A and group B according to treatment regimen. Both groups were given high-quality low-protein diet, and comprehensive treatments such as decrease of blood pressure, correction of anemia, supplementation of α-ketoacid, and correction of water, electrolyte and acid-base balances. Group A was administered 80 mg/d valsartan, based on which group B was given 40 mg/d febuxostat. Serum uric acid and high-sensitivity C-reactive protein levels were measured on the 2nd day after enrollment and after 2 mo of treatment, respectively. Echocardiographic examination was conducted. Before treatment, the two groups had similar serum levels of uric acid and high-sensitivity C-reactive protein (p>0.05). After treatment, such levels significantly decreased (p 0.05). After treatment left atrial diameter, left ventricular end diastolic diameter, left ventricular enddiastolic volume and left ventricular end-systolic volume significantly reduced, and ejection fraction and fraction shortening significantly increased (p